Literature DB >> 10964265

Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells.

B S McIntyre1, K P Briski, A Gapor, P W Sylvester.   

Abstract

Studies were conducted to determine the comparative effects of tocopherols and tocotrienols on preneoplastic (CL-S1), neoplastic (-SA), and highly malignant (+SA) mouse mammary epithelial cell growth and viability in vitro. Over a 5-day culture period, treatment with 0-120 microM alpha- and gamma-tocopherol had no effect on cell proliferation, whereas growth was inhibited 50% (IC50) as compared with controls by treatment with the following: 13, 7, and 6 microM tocotrienol-rich-fraction of palm oil (TRF); 55, 47, and 23 microM delta-tocopherol; 12, 7, and 5 microM alpha-tocotrienol; 8, 5, and 4 microM gamma-tocotrienol; or 7, 4, and 3 microM delta-tocotrienol in CL-S1, -SA and +SA cells, respectively. Acute 24-hr exposure to 0-250 microM alpha- or gamma-tocopherol (CL-S1, -SA, and +SA) or 0-250 microM delta-tocopherol (CL-S1) had no effect on cell viability, whereas cell viability was reduced 50% (LD50) as compared with controls by treatment with 166 or 125 microM delta-tocopherol in -SA and +SA cells, respectively. Additional LD50 doses were determined as the following: 50, 43, and 38 microM TRF; 27, 28, and 23 microM alpha-tocotrienol; 19, 17, and 14 microM gamma-tocotrienol; or 16, 15, or 12 microM delta-tocotrienol in CL-S1, -SA, and +SA cells, respectively. Treatment-induced cell death resulted from activation of apoptosis, as indicated by DNA fragmentation. Results also showed that CL-S1, -SA, and +SA cells preferentially accumulate tocotrienols as compared with tocopherols, and this may partially explain why tocotrienols display greater biopotency than tocopherols. These data also showed that highly malignant +SA cells were the most sensitive, whereas the preneoplastic CL-S1 cells were the least sensitive to the antiproliferative and apoptotic effects of tocotrienols, and suggest that tocotrienols may have potential health benefits in preventing and/or reducing the risk of breast cancer in women.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964265     DOI: 10.1046/j.1525-1373.2000.22434.x

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  52 in total

1.  Mechanisms Mediating the Synergistic Anticancer Effects of Combined γ-Tocotrienol and Celecoxib Treatment.

Authors:  Amit B Shirode; Paul W Sylvester
Journal:  J Bioanal Biomed       Date:  2011-01-10

2.  Effects of ultra-wideband electromagnetic pulses on pre-neoplastic mammary epithelial cell proliferation.

Authors:  P W Sylvester; S J Shah; D T Haynie; K P Briski
Journal:  Cell Prolif       Date:  2005-06       Impact factor: 6.831

3.  In Vitro Oxidation of Collagen Promotes the Formation of Advanced Oxidation Protein Products and the Activation of Human Neutrophils.

Authors:  Guilherme Vargas Bochi; Vanessa Dorneles Torbitz; Luízi Prestes de Campos; Manuela Borges Sangoi; Natieli Flores Fernandes; Patrícia Gomes; Maria Beatriz Moretto; Fernanda Barbisan; Ivana Beatrice Mânica da Cruz; Rafael Noal Moresco
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

4.  Tocotrienols fight cancer by targeting multiple cell signaling pathways.

Authors:  Ramaswamy Kannappan; Subash C Gupta; Ji Hye Kim; Bharat B Aggarwal
Journal:  Genes Nutr       Date:  2011-04-09       Impact factor: 5.523

5.  γ-Tocotrienol reversal of epithelial-to-mesenchymal transition in human breast cancer cells is associated with inhibition of canonical Wnt signalling.

Authors:  R A Ahmed; O A Alawin; P W Sylvester
Journal:  Cell Prolif       Date:  2016-06-21       Impact factor: 6.831

6.  Vitamin E inhibition of normal mammary epithelial cell growth is associated with a reduction in protein kinase C(alpha) activation.

Authors:  P W Sylvester; B S McIntyre; A Gapor; K P Briski
Journal:  Cell Prolif       Date:  2001-12       Impact factor: 6.831

7.  Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment.

Authors:  Vikram B Wali; Sunitha V Bachawal; Paul W Sylvester
Journal:  Lipids       Date:  2009-09-24       Impact factor: 1.880

8.  Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.

Authors:  Amit B Shirode; Paul W Sylvester
Journal:  Biomed Pharmacother       Date:  2009-11-14       Impact factor: 6.529

9.  Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.

Authors:  Sunitha V Bachawal; Vikram B Wali; Paul W Sylvester
Journal:  BMC Cancer       Date:  2010-03-08       Impact factor: 4.430

10.  Anti-proliferative effects of gamma-tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression.

Authors:  G V Samant; V B Wali; P W Sylvester
Journal:  Cell Prolif       Date:  2009-11-17       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.